Baseline characteristics and age-related macular degeneration in participants of the "ASPirin in Reducing Events in the Elderly" (ASPREE)-AMD trial.
Robman LD, Phuong Thao LT, Guymer RH, Wolfe R, Woods RL, Hodgson LA, Phung J, Makeyeva GA, Le-Pham YA, Orchard SG, Suleiman J, Maguire E, Trevaks RE, Ward SA, Riaz M, Lacaze P, Storey E, Abhayaratna WP, Nelson MR, Ernst ME, Reid CM, McNeil JJ; ASPREE Investigator Group.
Robman LD, et al.
Contemp Clin Trials Commun. 2020 Oct 11;20:100667. doi: 10.1016/j.conctc.2020.100667. eCollection 2020 Dec.
Contemp Clin Trials Commun. 2020.
PMID: 33210016
Free PMC article.
METHODS: Australian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized to 100 mg aspirin daily or placebo, had non-mydriatic, digital color fundus images graded according to the Beckman AMD classification. ...
METHODS: Australian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized to 100 mg aspirin daily or pl …